|
|
Volumn 337, Issue 6096, 2012, Pages 790-792
|
|
Stopping Alzheimer's before it starts
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID BETA PROTEIN;
BAPINEUZUMAB;
CRENEZUMAB;
SOLANEZUMAB;
APOLIPOPROTEIN E4;
MONOCLONAL ANTIBODY;
LITERATURE REVIEW;
NERVOUS SYSTEM DISORDER;
AGING;
ALZHEIMER DISEASE;
BRAIN DAMAGE;
BRAIN SCINTISCANNING;
COGNITION;
DRUG TREATMENT FAILURE;
GENE MUTATION;
HUMAN;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SHORT SURVEY;
ADULT;
CHILD;
CLINICAL TRIAL (TOPIC);
FEMALE;
GENETIC PREDISPOSITION;
GENETICS;
HETEROZYGOTE DETECTION;
INFORMATION SERVICE;
MALE;
METHODOLOGY;
NOTE;
NUCLEOTIDE SEQUENCE;
ONSET AGE;
PEDIGREE;
PRIMARY PREVENTION;
RISK;
ADULT;
AGE OF ONSET;
ALZHEIMER DISEASE;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
APOLIPOPROTEIN E4;
CHILD;
CLINICAL TRIALS AS TOPIC;
DNA MUTATIONAL ANALYSIS;
FEMALE;
GENETIC PREDISPOSITION TO DISEASE;
HETEROZYGOTE DETECTION;
HUMANS;
INFORMATION SERVICES;
MALE;
PEDIGREE;
PRIMARY PREVENTION;
RISK;
|
|
EID: 84865077476
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.337.6096.790 Document Type: Short Survey |
|
Times cited : (67)
|
|
References (0)
|
